Qiagen N.V.

  • ISIN: NL0012169213
  • Land: The Netherlands

Nachricht vom 12.03.2019 | 10:29

QIAGEN N.V.: Release of a capital market information

QIAGEN N.V. / Share Buyback

12.03.2019 / 10:29
Dissemination of a Post-admission Duties announcement transmitted by DGAP -
a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Disclosure according to Article 5 Section (1) and (6) of the EU Regulation 596/2014 in conjunction with Article 2 Section (2) and (3) of the Delegated EU Regulation 2016/1052 / Share Repurchase - Interim Reporting With disclosure dated December 19, 2018, QIAGEN N.V. announced pursuant to Article 5 Section (1) and (6) of the EU Regulation no 596/2014 and Article 2 Section (1) of the Delegated EU Regulation no 2016/1052 the immediate beginning of a third tranche of up to USD 70 million under the share repurchase program originally announced on January 31, 2018. In the context of this tranche the final shares have been bought back on the electronic trading platform of the Frankfurt Stock Exchange (XETRA) from March 4, 2019 until and including March 8, 2019 amounts to 115,695 shares. Shares were bought back as follows:

Date            Number of Shares   Average Price     Purchased Volume
                acquired           (EUR)             (EUR)
04 March 2019   23,053             34.7023           799,992.12
05 March 2019   23,118             34.6047           799,991.45
06 March 2019   23,036             34.7270           799,971.17
07 March 2019   23,245             34.4153           799,983.65
08 March 2019   23,243             34.5043           801,983.44
Total           115,695            34.5903           4,001,921.84

The underlying individual trades are published on the website of QIAGEN N.V. (http://corporate.qiagen.com/investor-relations/share-information/ share-buyback). The total number of shares which have already been bought back within the framework of such tranche of the share repurchase program from December 19, 2018 until and including March 8, 2019 amounts to 1,364,150 shares. The average purchase price per share was EUR 32.22 a total price of EUR 43,948,611.17 (excl. ancillary costs), which represents based on the ECB reference rate as of 18 December 2018 (EUR 1 = USD 1.1377) a USD amount of 50,000,334.93 was paid to buy back the shares. The purchase of the shares of QIAGEN N.V. was carried out by a financial institution that has been commissioned by QIAGEN N.V. We will report on the execution of further tranches of the buy-back program in due course. Venlo, 12 March 2019 Managing Board ### Contacts: QIAGEN Investor Relations John Gilardi +49 2103 29 11711 e-mail: ir@qiagen.com Public Relations Dr. Thomas Theuringer +49 2103 29 11826 e-mail: pr@qiagen.com
12.03.2019 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de
Language: English Company: QIAGEN N.V. Hulsterweg 82 5912 PL Venlo Netherlands Internet: www.qiagen.com End of News DGAP News Service


Expedeon AG mit attraktiver Produktpipeline

Durch die konsequente Fortsetzung der „Grow, Buy & Build“-Strategie hat die im Bereich der Entwicklung und Vermarktung von DNA-Technologien, Proteomik- und Antikörper-Konjugations-Anwendungen tätige Expedeon AG das Umsatzniveau angehoben und auf operativer Ergebnisebene zugleich den Break-Even nachhaltig überschritten. Für die kommenden Perioden ist der Ausbau der Umsatzerlöse mit den bestehenden Produkten geplant. Darüber hinaus verfügt die Expedeon AG über eine attraktive Produktpipeline mit hohem Umsatzpotenzial. Unser Kursziel liegt bei 3,20 € je Aktie. Das Rating lautet KAUFEN.

News im Fokus

Wirecard AG: Statement zum Artikel der Financial Times

16. Oktober 2019, 09:01

Aktuelle Research-Studie

Original-Research: Klondike Gold Corp (von First Berlin Equity Research GmbH): BUY Klondike Gold Corp

17. Oktober 2019